<DOC>
	<DOCNO>NCT03078569</DOCNO>
	<brief_summary>This study evaluate efficacy pre- IVF treatment transdermal testosterone enhance ovarian response poor responder . randomize controlled trial two group , treatment group transdermal testosterone IVF treatment control group treatment .</brief_summary>
	<brief_title>Transdermal Testosterone Poor Responder Patients Undergoing Controlled Ovarian Stimulation Prior IVF</brief_title>
	<detailed_description>One major challenge Assisted reproduction technology treat woman low ovarian response , woman achieve poor pregnancy rate IVF . recent year focus</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Infertility , Female</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>infertility patient undergoing ART regular menses normal function thyroid , liver kidney normal BMI ( 19.328.9 ) without use fertility drug previous two month patient recurrent implantation failure ( 3 cycle ) previous ovarian surgery uncontrolled medical illness severe endometriosis ( stage 34 ) contraindication testosterone use</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Poor responder</keyword>
</DOC>